Biosynthesis specialist Antheia has topped off its series C funding with a second close, adding $24 million more to its haul. The financing lift brings Antheia's total funding over the past year to ...
Antheia, a biomanufacturer that makes a key ingredient for the opioid overdose treatment Narcan, reeled in $56 million in a series C financing. The company plans to use the funds to expand ...
The company received the money through a government project agreement. Antheia announced that it has received $17 million in funding to be used for projects focused on building domestic pharmaceutical ...
MENLO PARK, Calif., Jan. 27, 2026 /PRNewswire/ -- Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has completed a ...
MENLO PARK, Calif. and MILAN, Italy, March 13, 2024 (GLOBE NEWSWIRE) -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, and Olon Group, the global ...
From the San Francisco Business Times. Long before the Covid-19 pandemic and President Donald Trump's recent call for domestic drug manufacturing, Christina Smolke and Kristy Hawkins could see a need ...
MENLO PARK, Calif., Oct. 21, 2025 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the appointment of Eric d'Esparbes ...
Synthetic biology company Antheia has secured $40M in debt financing from Silicon Valley Bank and Oxford Finance LLC, as part of a plan to build a new biomanufacturing facility, expected to be ...
MENLO PARK, Calif., June 30, 2021 /PRNewswire/ -- Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, announced today that it has raised $73M in Series B financing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results